Caribou Biosciences (CRBU)
NASDAQ:CRBU
Want to see CRBU full AI Analyst Report?
Top Page
Caribou Biosciences
(NASDAQ:CRBU)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.50
▲(13.64% Upside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak financial performance (sharp revenue decline, large operating losses, and significant ongoing cash burn). Technical indicators are mixed but lean slightly negative, and valuation is not meaningfully supported due to losses (negative P/E). The RMAT designation is a notable positive catalyst, but it is not enough to offset the current financial and cash-flow risks.
Positive Factors
Proprietary CRISPR platform
Caribou’s chRDNA-guided CRISPR platform and focus on allogeneic (off-the-shelf) immune cell therapies represent a durable technical and IP advantage. This platform enables scalable manufacturing, potential royalty/licensing revenues and differentiation versus autologous approaches, supporting long-term partnership and commercialization prospects.
Negative Factors
Persistent cash burn
Deeply negative operating and free cash flow are a durable constraint on strategy: sustained cash burn requires frequent external financing or dilutive raises, limits ability to fund multiple trials concurrently, and elevates execution risk if capital markets tighten, affecting long-term program continuity.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary CRISPR platform
Caribou’s chRDNA-guided CRISPR platform and focus on allogeneic (off-the-shelf) immune cell therapies represent a durable technical and IP advantage. This platform enables scalable manufacturing, potential royalty/licensing revenues and differentiation versus autologous approaches, supporting long-term partnership and commercialization prospects.
Read all positive factors
Caribou Biosciences (CRBU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$204.81M
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)2.32
Revenue Growth12.96%
EPS Growth12.51%
CountryUS
Employees147
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.42
Shares Outstanding99,180,570
10 Day Avg. Volume1,354,975
30 Day Avg. Volume1,199,069
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.22
Price to Sales (P/S)13.31
P/FCF Ratio-1.32
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue22.22
Enterprise Value/Gross Profit23.59
Enterprise Value/Ebitda-2.14
Forecast
1Y Price Target
$9.17Price Target Upside316.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.16
Revenue Forecast (FY)$23.61M
Caribou Biosciences Business Overview & Revenue Model
Company Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. I...
How the Company Makes Money
Caribou Biosciences primarily generates revenue through collaboration and licensing arrangements tied to its genome-editing technologies and development programs. These agreements typically include upfront payments, research funding or cost reimbu...
Caribou Biosciences Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.20M | 11.16M | 9.99M | 34.48M | 13.85M | 9.60M |
| Gross Profit | 10.55M | 7.51M | 6.07M | 30.95M | 10.21M | 8.61M |
| EBITDA | -116.43M | -132.55M | -162.69M | -112.53M | -95.71M | -65.61M |
| Net Income | -133.22M | -148.13M | -149.10M | -102.07M | -99.42M | -66.92M |
Balance Sheet | ||||||
| Total Assets | 149.00M | 175.37M | 313.31M | 432.21M | 373.76M | 442.36M |
| Cash, Cash Equivalents and Short-Term Investments | 117.63M | 139.34M | 209.54M | 328.83M | 247.66M | 375.83M |
| Total Debt | 26.95M | 27.23M | 26.49M | 27.11M | 27.75M | 259.00K |
| Total Liabilities | 46.98M | 53.19M | 60.36M | 63.81M | 72.89M | 54.53M |
| Stockholders Equity | 102.02M | 122.17M | 252.95M | 368.40M | 300.87M | 387.82M |
Cash Flow | ||||||
| Free Cash Flow | -101.64M | -112.35M | -144.71M | -104.90M | -97.42M | -35.64M |
| Operating Cash Flow | -101.25M | -110.99M | -138.20M | -93.29M | -90.97M | -32.52M |
| Investing Cash Flow | 76.84M | 102.24M | 86.61M | -68.18M | -93.25M | -176.40M |
| Financing Cash Flow | 7.05M | 4.82M | 16.72M | 154.30M | 2.13M | 433.43M |
Caribou Biosciences Technical Analysis
Negative
2.20
Price Trends
2.06
Negative
1.89
Positive
1.95
Negative
Market Momentum
0.02
Positive
41.60
Neutral
12.79
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBU, the sentiment is Negative. The current price of 2.2 is above the 20-day moving average (MA) of 2.12, above the 50-day MA of 2.06, and above the 200-day MA of 1.95, indicating a bearish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 41.60 is Neutral, neither overbought nor oversold. The STOCH value of 12.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBU.
Caribou Biosciences Risk Analysis
Caribou Biosciences disclosed 84 risk factors in its most recent earnings report. Caribou Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Caribou Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $265.87M | -6.01 | -2748.16% | ― | ― | 43.68% | |
50 Neutral | $572.32M | -2.08 | -131.58% | ― | ― | 22.16% | |
50 Neutral | $775.94M | >-0.01 | 87.31% | ― | ― | -1004.74% | |
46 Neutral | $224.19M | -4.55 | -80.61% | ― | 43.21% | -15.55% | |
45 Neutral | $204.81M | -1.38 | -100.13% | ― | 12.96% | 12.51% | |
43 Neutral | $87.27M | -0.68 | 6686.36% | ― | -45.80% | -0.16% |
* Healthcare Sector Average
CRBU
Caribou Biosciences
1.92
0.65
51.18%
SGMO
Sangamo Therapeutics
0.22
-0.30
-57.84%
CLLS
Cellectis SA
3.06
1.64
115.49%
CABA
Cabaletta Bio
3.25
0.88
37.13%
ELTX
Elicio Therapeutics
13.26
5.29
66.37%
VOR
Vor Biopharma
13.16
8.70
195.07%
Caribou Biosciences Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Caribou Biosciences Gains RMAT Status for CB-011 Therapy
Positive
Mar 31, 2026
On March 31, 2026, Caribou Biosciences announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to CB-011, its allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myelo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.